Altre lingue ProQR Therapeutics N.V.

Azioni

PRQR

NL0010872495

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
1,96 ^USD	-2,49%		+5,38%	-1,01%

14/03	PROQR THERAPEUTICS N.V. : Chardan Research mantiene la raccomandazione Buy	ZM
13/03	ProQR Therapeutics N.V. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting	23/04
ProQR Therapeutics N : AGM 2024 Notice and Agenda	23/04
ProQR Therapeutics N : AGM 2024 AoA one-tier Board Dutch redline	23/04
ProQR Therapeutics N : AGM 2024 AoA one-tier Board Dutch clean	23/04
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English redline	23/04
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English clean	23/04
ProQR Therapeutics N : AGM 2024 Board Compensation Policy one-tier Board	23/04
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board redline	23/04
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board clean	23/04
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024	23/04
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting	22/04
ProQR Therapeutics N : AGM 2024 Explanatory Notes	22/04
ProQR Therapeutics N : AGM 2024 POA Registered Shareholders	22/04
ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio	22/04
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio	19/04
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
ProQR Announces Year End 2023 Operating and Financial Results	13/03
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing	15/02
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024	19/01
ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration	05/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ProQR Therapeutics N.V.

Azioni

PRQR

NL0010872495

Altre lingue

Filtri